Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection
Sign Up to like & getrecommendations! Published in 2025 at "JCI Insight"
DOI: 10.1172/jci.insight.181496
Abstract: BACKGROUND HIV-1–specific broadly neutralizing monoclonal antibodies (bNAbs) have emerged as promising interventions with the potential to effectively treat and prevent HIV-1 infections. We conducted a phase I clinical trial evaluating the potent CD4-binding site–specific (CD4bs-specific)… read more here.
Keywords: vrc01ls vrc07; hiv; trial; broadly neutralizing ... See more keywords
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Sign Up to like & getrecommendations! Published in 2025 at "BMC Immunology"
DOI: 10.1186/s12865-025-00687-7
Abstract: VRC07-523LS is a safe and well-tolerated monoclonal antibody (mAb) targeting the CD4 binding site on the HIV envelope (Env) trimer. Efficacy of VRC07-523LS, in combination with mAbs targeting other HIV epitopes, will be evaluated in… read more here.
Keywords: monoclonal antibody; hiv; vrc07 523ls; analysis three ... See more keywords